Launch
FDA approves durvalumab for limited-stage small cell lung cancer
What's New: Drugs RSS Feed · By FDA ·
The Brief
- On December 4, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer.
- The approval covers adults whose disease has not progressed after concurrent platinum-based chemotherapy and radiation therapy.
- The sources provide no trial data, survival figures or safety details.
Why it matters
It adds an approved immunotherapy option for a specific group of limited-stage small cell lung cancer patients, which is relevant to oncology researchers and clinicians following treatment guidelines.
Who’s affected
- Adults with limited-stage small cell lung cancer whose disease has not progressed after concurrent platinum-based chemoradiation
- #oncology
- #drug-approval
- #small-cell-lung-cancer
- #durvalumab
- #fda
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Timeline
FDA approves durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed after concurrent platinum-based chemotherapy and radiation therapy
What's New: Drugs RSS Feed
FDA approves durvalumab for limited-stage small cell lung cancer